Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. - Wikidata - awgldk - TriplyDB

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.

http://www.wikidata.org/entity/Q37363395

about

Advances in mass spectrometry-based clinical biomarker discovery Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers Biomarkers in prostate cancer: what's new?Precision medicine: from pharmacogenomics to pharmacoproteomics Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence Multiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins.Biomarkers of HIV-associated Cancer.Insufficient antibody validation challenges oestrogen receptor beta research.Validation of a blood protein signature for non-small cell lung cancer Use of autoantibodies to detect the onset of breast cancer Biomarkers of PTSD: military applications and considerations.Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.Improving the quality of biomarker discovery research: the right samples and enough of them A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma Interaction of Serum Antibodies from Breast Cancer Patients with Synthetic Peptides.Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics Cancer biomarker discovery using DNA aptamers.Biomarkers for Bone Tumours: Discovery from Genomics and Proteomics Studies and Their Challenges.Adsorbing/dissolving Lyoprotectant Matrix Technology for Non-cryogenic Storage of Archival Human Sera Biomarker discovery in mass spectrometry-based urinary proteomics.A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural Effusions Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors.Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.Cancer biomarker discovery: current status and future perspectives.Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.Advances in urinary proteome analysis and applications in systems biology.Important options available--from start to finish--for translating proteomics results to clinical chemistry.CE-MS-based proteomics in biomarker discovery and clinical application.Relative versus absolute quantitation in disease glycomics.Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.Recent findings from the Human Proteome Project: opening the mass spectrometry toolbox to advance cancer diagnosis, surveillance and treatment.Cancer proteomics: developments in technology, clinical use and commercialization.Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.

P2860

Q26770004-F25464EC-F662-4C74-A36E-2E490DEF87F3 Q27001445-9686B015-E1A0-4C3F-BFFB-F80F811BAE33 Q27026210-C29631ED-37E5-4443-907C-62DA40623A7F Q28076871-7EA104A8-E5D5-40CE-B8E9-6CEB85022829 Q33603691-2F4926C0-25B8-4093-8ADD-7E763E495188 Q33759991-B421A4CE-E4AA-4356-8A66-4E7E8AF173C4 Q33764870-6DB47EE8-AE09-42E1-B407-04D4ADFE4BDA Q33856851-39FA2FD2-BEA9-474B-A793-8908006462B3 Q33885342-9765DAC1-17D3-43CB-A8DB-0069BE1127EC Q34008245-F71D2B67-9830-4DE9-B424-4762F1B4E3C9 Q34037876-5875025F-39DB-4146-8201-BE6BDBA129BD Q34068752-B0D51867-0661-4B63-943F-2F2E0E017DC8 Q34267969-2B490C9B-DCC6-4523-BA8E-CB17BCDAEA88 Q35273633-1FE0F0D4-1AC7-4A9A-A577-4C88C72D377F Q35325472-E4EF9CF5-7D73-4D2D-824D-C5CB02032B99 Q35674848-398368FB-B020-481C-84A8-0AE204E8C42A Q36052565-34A398CE-FE70-45DC-9FF2-BF062A30BA9A Q36171505-631F3D8B-BACE-4F47-9AC7-176906AD7AE9 Q36174786-725818D6-6B86-4377-AF8C-FB475D5EF18C Q36430835-320DE0A3-8C1F-4FF7-8F21-85D1FB04D9B4 Q36430991-D2124517-D6D2-42F7-9291-D7BBA4106A21 Q36758011-4CE38D4A-6122-4F05-BF7B-26D49C4BA732 Q36789976-73608262-9702-43DB-AE4E-EA6E22CFF546 Q36956324-B94B9631-4ECE-4F92-ACC2-A338471305BC Q37112709-FEA7D99C-D4DE-414B-8110-C3D9C26853E9 Q37322221-8D7B0754-F163-4E84-9DF7-7D53EE3157D3 Q37714579-BEE8EAE2-0EFD-4340-B961-9FDEAB6C9954 Q38183147-7367BEB9-0E80-4526-A0EE-3C226FE2D5BA Q38187679-742B6E66-DE93-4858-BE5F-8A91A28EF8CF Q38203040-823A0A82-F473-431F-AEE6-1E4A31DFF7FB Q38207538-69B7DE1B-968F-44DF-8DA9-18DDFE3C186B Q38269864-AF862694-4FE7-4E36-A9C0-300F8F287C9B Q38282797-100C2FB4-DE88-421C-A7A0-05F129A207FF Q38340358-9C1DDA9B-6457-4ACB-B99D-067A51A95399 Q38356585-301DF5C4-3A10-4CA1-B5EA-7E89871D2DCF Q38384848-DCA09667-BB9D-453C-B95A-59BCA1F312C6 Q38418590-4BB07E94-68F4-4938-AA01-E51CBEC3E200 Q38449763-68EC25D1-1242-444E-A996-FE8EE66DEE05 Q38543009-9E2DBF75-70F1-4BF0-800D-123AB0FB8D60 Q38552059-170AEF82-DF65-4720-9A0C-AED00020FEFD

P2860

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.

http://www.wikidata.org/entity/Q37363395

description

2013 թվականի հոկտեմբերի 2-ին հրատարակված գիտական հոդված

@hy

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

name

Translation of proteomic bioma ...... ostics: issues and challenges.

@en

Translation of proteomic bioma ...... ostics: issues and challenges.

@nl

type

label

Translation of proteomic bioma ...... ostics: issues and challenges.

@en

Translation of proteomic bioma ...... ostics: issues and challenges.

@nl

prefLabel

Translation of proteomic bioma ...... ostics: issues and challenges.

@en

Translation of proteomic bioma ...... ostics: issues and challenges.

@nl

P1433

Q37363395-3ED8D1EC-B4C9-431E-9BED-879E9CACFD46

P1476

Q37363395-27B54E0B-02C4-43BC-B40C-D035F814AAF6

P2093

Q37363395-1A4C9BAF-8EC2-47D6-9AD0-E1B0F3B78441

Q37363395-437ABB0E-7F9E-4836-A0BD-01443AACAB95

Q37363395-7696F315-264A-45EC-A2D7-2B773F6897CE

Q37363395-EE734475-1382-45ED-BCF8-C2DE90E38970

P2860

Q37363395-0025871D-8573-4308-8CA9-CFB284A0CBF5

Q37363395-02C74BA9-A973-4994-807F-2F632A5363BA

Q37363395-0BD507F8-E132-41F9-9FD8-7E4933F96FEE

Q37363395-0DA0BD11-E853-4E86-A50D-4A5A4A2E1A11

Q37363395-0FBF2C9E-0109-4777-AC8A-E720EE47FF18

Q37363395-1D765D62-AB68-4F06-8098-6D95753CC73B

Q37363395-2B18A80E-3B45-4F83-8466-274392BB1B56

Q37363395-2BB74FB4-C234-4F74-BF1A-05264170F5F2

Q37363395-352334CB-64CE-42FE-9A5A-EF0B63ECBD0E

Q37363395-35CDA656-7815-445E-9C4A-AF4AFD9B1513

P2888

Q37363395-A779465F-B8BB-45F2-9763-A93B79C32272

P304

Q37363395-7BD6C344-F4AE-4CAA-B060-FBBE7F44E8CF

P31

Q37363395-B2EE172E-1402-4871-9178-7AF796109314

P356

Q37363395-6D290C06-8DD6-4BCF-81A2-AF80A4ED9B42

P433

Q37363395-4436DC8A-AA74-43E3-9D71-8E8BA9FA0E56

P478

Q37363395-21A6E5D1-0F83-4156-A92A-77992ADAA079

P577

Q37363395-3819B3C6-3971-4708-9BD6-62947AF66A53

P5875

Q37363395-83B066D7-F252-4D5A-8DCE-7E964FB819B6

P698

Q37363395-208A3680-9407-4B0E-9C04-30D30AE55E86

P921

Q37363395-A751BF76-5303-43A6-A7A6-A3D13552FF14

Q37363395-e83b32f7-3c3c-4a1b-9625-2a8f2bad4362

P932

Q37363395-4A501DE3-9EF0-4F1D-8872-72436E36A035

P356

1559-0275-10-13

P1433

Clinical Proteomics

P1476

Translation of proteomic bioma ...... ostics: issues and challenges.

@en

P2093

Anna K Füzéry

http://www.w3.org/2001/XMLSchema#string

Daniel W Chan

http://www.w3.org/2001/XMLSchema#string

Joshua Levin

http://www.w3.org/2001/XMLSchema#string

Maria M Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Beyond diagnostic accuracy: the clinical utility of diagnostic tests

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Within-subject biological variation in disease: collated data and clinical consequences.

A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance.

Biomarker discovery and clinical proteomics.

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Cancer biomarkers: can we turn recent failures into success?

Phases of biomarker development for early detection of cancer.

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Laboratory results. Timeliness as a quality attribute and strategy.

P2888

1559-0275-10-13

P304

13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1559-0275-10-13

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257309099

http://www.w3.org/2001/XMLSchema#string

P698

24088261

http://www.w3.org/2001/XMLSchema#string

P921

P932

3850675

http://www.w3.org/2001/XMLSchema#string